| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/01/2004 | WO2003072048A3 Symptomatic relief of gastrointestinal disorders |
| 07/01/2004 | WO2003051278A3 Nanoparticle delivery vehicle |
| 07/01/2004 | WO2002099083A3 Gfats as modifiers of the p53 pathway and methods of use |
| 07/01/2004 | US20040128707 Animal model for pancreatic disorder associated with signal transduction; obesity prevention |
| 07/01/2004 | US20040127884 Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis |
| 07/01/2004 | US20040127826 Honey in wound dressings |
| 07/01/2004 | US20040127708 antiviral activities; aids treatment |
| 07/01/2004 | US20040127696 Growth differentiation factor-7 |
| 07/01/2004 | US20040127686 Signal transduction regulator binding protein for identifying modulators for prevention and treatment of cardiomyopic hypertrophy, heart failure and diabetes; drug screening |
| 07/01/2004 | US20040127572 the prevention or amelioration of sleep-related breathing disorders such as sleep apnea |
| 07/01/2004 | US20040127571 Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate |
| 07/01/2004 | US20040127568 Therapeutic use of D-methionine to reduce the toxicity of radiation |
| 07/01/2004 | US20040127556 Administering limonoid comprising toosendanin and/or azadirachtin plant extracts; aging resistance; muslce relaxation by inhibiting acetylcholine release at neuromuscular junctions |
| 07/01/2004 | US20040127550 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy |
| 07/01/2004 | US20040127539 Antiangiogenic combination therapy for the treatment of cancer |
| 07/01/2004 | US20040127492 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
| 07/01/2004 | US20040127489 Novel antipsychotic combination therapies and compositions useful therein |
| 07/01/2004 | US20040127481 Administering a therapeutic amount of a lidocaine, verapamil, diltiazem, isometheptene, or lisuride condensation aerosol |
| 07/01/2004 | US20040127474 Contacting the cell with a ptc agonist in a sufficient amount to inhibit the altered growth state, wherein the ptc agonist is a organic molecule having a molecular weight less than about 750 amu for inhibiting an altered growth state of a cell |
| 07/01/2004 | US20040127470 Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| 07/01/2004 | US20040127454 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases |
| 07/01/2004 | US20040127437 Combined therapeutical treatment of hyperproliferative diseases |
| 07/01/2004 | US20040127428 Use of D-ribose, including as a topical vehicle, to promote faster healing, including from surgical procedures |
| 07/01/2004 | US20040127427 Ketoamide inhibitors in chronic nerve disease |
| 07/01/2004 | US20040127425 Control of nitric oxide bioactivity by perfluorocarbons |
| 07/01/2004 | US20040127410 Circular permuteins of flt3 ligand |
| 07/01/2004 | US20040127404 Methods for treating autoimmune diseases |
| 07/01/2004 | US20040126863 Comprises amino acid sequences for use in identifying modulators for diagnosis and treatment of respiratory and diabetes-induced peripheral vascular diseases; mimetics |
| 07/01/2004 | US20040126825 Using a compounds ability to decrease integrin activation as a diagnostic tool for the identification of antagonistic modulators of neovascularizaton; antitumor/antiproliferative agents |
| 07/01/2004 | US20040126810 Peptide substrate identified by type bont/b botulinus toxin and use thereof for assaying and/or detecting said toxin or corresponding inhibitors |
| 07/01/2004 | US20040126759 Molecules for disease detection and treatment |
| 07/01/2004 | US20040126758 homologous to the known fibrinogen derived haptotactic peptides; shown to elicit activity from fibroblasts, endothelial and smooth muscle cells; for wound healing and enhancing osteogenesis/angiogenesis in vivo with/without medical implant |
| 07/01/2004 | US20040126436 Mixture of bicarbonate and enzyme for rermoval of ear wax from ear canal |
| 07/01/2004 | US20040126432 Blood flow enhancer and inflamation reducer, anticholesterol agents and oxidation reduction |
| 07/01/2004 | US20040126428 comprises opiates; |
| 07/01/2004 | US20040126426 comprises paclitaxel, cisplatin, and hyaluronic acids; bioresorption; radiotherapy; for treatment of cancer |
| 07/01/2004 | US20040126423 Pharmaceutical formulation |
| 07/01/2004 | US20040126417 Transdermal buprenorphine to treat pain in sickle cell crisis |
| 07/01/2004 | US20040126380 Administering a neurotoxin ; therapy for enlargement of prostate gland |
| 07/01/2004 | US20040126379 Complex containing antibody and cytotoxic compound |
| 07/01/2004 | US20040126366 Autism, attention deficit , obsessive complusive disorders , mental retardation |
| 07/01/2004 | US20040126360 Oral formulations for proteins and polypeptides |
| 07/01/2004 | US20040126359 Modulate lymphocyte activation; cell proliferation; apoptosis; signal transduction |
| 07/01/2004 | US20040126356 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 07/01/2004 | US20040126329 Delivery of analgesics through an inhalation route |
| 07/01/2004 | US20040126328 Arerosol; heating drug, vaporization, cooling |
| 07/01/2004 | US20040126327 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 07/01/2004 | US20040126326 Delivery of antidepressants through an inhalation route |
| 07/01/2004 | US20040126324 Mixture of ion exchange resin and drug |
| 07/01/2004 | US20040126323 Transdermal dosage form comprising an active agent and a salt and free-base form of an adverse agent |
| 07/01/2004 | CA2679030A1 Alpha-2-delta ligand to treat lower urinary track symptoms |
| 07/01/2004 | CA2509616A1 Combination therapy for the treatment of pain |
| 07/01/2004 | CA2509615A1 Gabapentin analogues for fibromyalgia and other related disorders |
| 07/01/2004 | CA2509611A1 Method of treatment for sexual dysfunction |
| 07/01/2004 | CA2509600A1 Pharmaceutical uses for alpha2delta ligands |
| 07/01/2004 | CA2509215A1 Method for identifying modulators of human orexin-2 receptor |
| 07/01/2004 | CA2508823A1 Method and reagents for treating or preventing atherosclerosis and diseases associated therewith |
| 07/01/2004 | CA2508297A1 Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
| 07/01/2004 | CA2505788A1 Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
| 07/01/2004 | CA2505406A1 Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate |
| 06/30/2004 | WO2004060326A1 Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
| 06/30/2004 | EP1433781A1 Pyrrolidine carboxylic acid derivatives |
| 06/30/2004 | EP1433482A1 Aqueous preparation containing a shark-derived chondroitin iron sulfate colloid |
| 06/30/2004 | EP1433479A1 Appetite-stimulating agents and remedies for anorexia |
| 06/30/2004 | EP1433477A2 External skin treatment stabilized composition comprising retinol |
| 06/30/2004 | EP1432821A2 A method for the early detection of cancer |
| 06/30/2004 | EP1432801A2 Receptors and membrane-associated proteins |
| 06/30/2004 | EP1432792A2 Histone deacetylase 9 |
| 06/30/2004 | EP1432738A1 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them |
| 06/30/2004 | EP1432736A2 METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l) |
| 06/30/2004 | EP1432734A1 Cytokine receptor |
| 06/30/2004 | EP1432732A2 Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state |
| 06/30/2004 | EP1432714A2 Chemical compounds |
| 06/30/2004 | EP1432711A1 1,6-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432710A1 1, 8-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432708A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity |
| 06/30/2004 | EP1432691A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
| 06/30/2004 | EP1432679A1 Preparation and use of pyrrole derivatives for treating obesity |
| 06/30/2004 | EP1432458A1 Inhibition of exoproteins using isoprenoids |
| 06/30/2004 | EP1432452A2 Inhibition of stat-1 |
| 06/30/2004 | EP1432448A2 Novel molecules of the hkid-1-related protein family and uses thereof |
| 06/30/2004 | EP1432440A2 Adjuvants for nucleic acid vaccines |
| 06/30/2004 | EP1432438A2 Use of rank antagonists to treat cancer |
| 06/30/2004 | EP1432436A2 Nutrient therapy for immuno-compromised patients |
| 06/30/2004 | EP1432435A1 Enamel matrix protein compositions for modulating immune response |
| 06/30/2004 | EP1432431A2 Methods and compositions for modulating interleukin-21 receptor activity |
| 06/30/2004 | EP1432425A1 A method of reducing the "in vivo" cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl) |
| 06/30/2004 | EP1432423A2 Pharmaceutical combinations of pde-v inhibitors and other agents |
| 06/30/2004 | EP1432422A2 Use of c-kit inhibitors for the treatment of myeloma |
| 06/30/2004 | EP1432421A1 Quinoline derivatives as neuropeptide y antagonists |
| 06/30/2004 | EP1432410A2 Process for the preparation of fast dissolving effervescent dosage form |
| 06/30/2004 | EP1432403A2 Liposome loading with metal ions |
| 06/30/2004 | EP1432402A2 Compositions for delivery of drug combinations |
| 06/30/2004 | EP1432379A1 Methods for inhibiting cognitive deterioration in adults with down's syndrome |
| 06/30/2004 | EP1326851B1 Substituted dipeptides as growth hormone secretagogues |
| 06/30/2004 | EP1267916B1 Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance |
| 06/30/2004 | EP1237543A4 Effervescent histamine h2 antagonist composition |
| 06/30/2004 | EP1178982B1 Heterocyclic substituted aminoazacycles useful as central nervous system agents |
| 06/30/2004 | EP1054688B1 Method for selecting tumours expressing hla-g, sensitive to anticancer treatment and uses |
| 06/30/2004 | EP1009421B1 Compositions for enhanced wound healing |